Acute Care Therapeutics for Surgical Settings
ANJESO® (meloxicam) injection
ANJESO® (meloxicam) injection was approved in February 2020 and is the first and only once-daily IV analgesic. ANJESO is indicated in adults for the treatment of moderate to severe pain, alone or in combination with non-NSAID analgesics. Because of delayed onset of action, ANJESO alone is not recommended for use when rapid acting analgesia is required.
– Up to 24 hours pain relief*
– Demonstrated safety and tolerability
– COX-2 preferential IV NSAID†
– Once-daily IV push
*When initiating ANJESO, monitor patient pain response. If patient experiences inadequate analgesia during the 24-hour dosing interval, consider adding a short-acting, non-NSAID, immediate-release analgesic.1
†The mechanism of action of ANJESO, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-2 activity is based on in vitro data, not clinical trial data.1
COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug.
Visit the ANJESO virtual booth.
Meet with us in the AAHKS app! Tap the Attendees & Exhibitors icon; filter for Exhibitors. Click Connect next to our name, and we’ll contact you with a time to speak.